

Non CF Bronchiectasis

by Dr Suzanne Carter & Dr Melissa McDonnell, Galway University Hospital,



Definition

Abnormal bronchial wall thickening and luminal dilatation of central and medium sized bronchi.

Epidemiology


566 Female vs 486 Male cases/100,000. Increases in those over 60 years of age

Clinical Features

- Cough:** >8 weeks with purulent sputum, bronchial infection and abnormal permanent dilation of bronchi, bronchial wall thickening, mucus plugging.
- Chronic Airway Infection**
- Exacerbations:** (50% will have 2 or more/year) associated with mortality, quality of life, lung function and further exacerbations.
- Dyspnoea**
- Haemoptysis**

Aetiology

Idiopathic	50% idiopathic (less likely if <50 at onset or rapidly progressive)
Associated Respiratory Diseases:	Asthma 40% of asthmatics with difficult to control asthma have radiological evidence of bronchiectasis. 27% of patients with bronchiectasis also have asthma. COPD (54.3% have both, more common in males with OR 1.62, higher if severe AFO and exacerbations, consider in COPD if 2 or more exacerbations per year or <i>Pseudomonas Aeruginosa</i> cultured) ABPA seen in 1-11% cases Alpha 1 antitrypsin deficiency cause in 1% of cases - suspect in basal emphysema PCD 0.9-10% see PCD Infection: Childhood measles, pneumonia, TB, whooping cough Localised Disease: Foreign Body, Tumour, Tracton
Immunodeficiency	5.8% have immunodeficiency: isolated IgA deficiency or CVID (IgG, IgA and sometimes IgM), X linked Agammaglobulinemia (reduction in all classes)
Inflammatory Diseases	Rheumatoid Arthritis 2-5% of cases caused by RA (lung disease can precede arthritis) Other CTD 5% Inflammatory Bowel Disease 1-3%
Aspiration	1-11% have symptoms of aspiration (Hiatus Hernia, Tracheo-oesophageal Fistula, Neurological Disease)
Rare Causes	Congenital: Williams Campbell Syndrome (tracheobronchomalacia), Mounier Kuhn syndrome (bronchomegaly), Lung sequestration Acquired: Young syndrome – obstructive azoospermia, rhinosinusitis - mercury poisoning. Yellow Nail Syndrome: pleural effusions, lymphoedema



Treatment

Maintenance Therapy	<ul style="list-style-type: none"> Physiotherapy: <ul style="list-style-type: none"> OD/BD >10 but <30 mins CT to tailor technique Review after 3 month Avoid head down if GORD NIV useful if early fatigue or exacerbation Modify if haemoptysis Hypertonic Saline Pulmonary Rehabilitation Vaccines: Flu, Pneumonia, COVID-19 LABA/LAMA low grade evidence ICS/PO steroids only with co-existing disease e.g. asthma/abpa (may have a role IBD associated bronchiectasis) Treatment of cause (e.g. Immunodeficiency, GORD) Monitor: BMI, Sputum Culture, Sats, Consider severity scoring (Bronchiectasis Severity Index/ FACED score)
Exacerbation Treatment	<ul style="list-style-type: none"> Minimum 14 days up to 21days Tailor to clinical response and microbiology (note in vitro and in vivo antibiotic sensitivities can differ) Anti-Pseudomonas Beta-Lactam +/- aminoglycoside Massive haemoptysis: bronchial artery embolization/surgery
Eradication Therapy	<p><i>Pseudomonas Aeruginosa:</i></p> <ol style="list-style-type: none"> Oral (ciprofloxacin) or IV therapy x 2/52 3 months inhaled agent (colomycin/gentamicin/tobramycin)
Long Term Antibiotics	<ul style="list-style-type: none"> Consider if >3 exacerbations/yr <i>Pseudomonas Negative:</i> azithromycin 250-500mg alt days/daily <i>Pseudomonas Positive:</i> Inhaled Colomycin/Gentamicin +/- po azithromycin
Advanced Disease	<ul style="list-style-type: none"> NIV Oxygen Surgery Transplant

Laboratory Tests

Bloods:	<ul style="list-style-type: none"> FBC, Serum Protein Electrophoresis. Total IgE Aspergillus specific IgE/Skin test Pneumococcal (PPV23) anti-body response (4 fold at 4-6 weeks) * if low immunoglobulin levels/low normal Connective Tissue Disease work up: * if features suggestive: Rheumatoid Factor, Anti CCP, ENA,ANA/ANCA Alpha-1 Antitrypsin Levels HIV test - depending on population prevalence
Sputum	<ul style="list-style-type: none"> Minimum yearly, at least 1 for AFB pre long term macrolides.

Imaging

Chest Radiograph:	<ul style="list-style-type: none"> Parallel line opacities (tram tracking), Tubular Opacities (mucus filled bronchi), Ring opacities (Dilated end-on bronchi). Abnormal in 87.8% but specificity 74%. Useful at baseline as comparator. 	
CT features	<ul style="list-style-type: none"> Bronchus > Artery (broncho-arterial ratio >1.5) (signet ring) Lack of tapering (airway visible within 1cm of pleura) Features specific to aetiology: CF -upper lobe, PCD -middle lobe, Alpha 1 – emphysema, ABPA - infiltrates 	

Bronchoscopy :	<ul style="list-style-type: none"> Focal disease to out rule foreign body/lesion. Not expectorating and clinically deteriorating
Pulmonary Function Tests	<ul style="list-style-type: none"> Obstructive in over 50% but can be restrictive/mixed/normal

Specific Tests

Investigations:	<ul style="list-style-type: none"> Sweat Test, Genetic Testing Features: Younger patients, upper lobe predominance, nasal polyps, chronic rhino sinusitis, recurrent pancreatitis, male infertility, malabsorption)
Primary Ciliary Dyskinesia Investigations (PCD):	<ul style="list-style-type: none"> Nasal Nitric Oxide, nasal NO, brushings, genetic testing Features: productive cough since childhood, situs inversus, congenital heart disease, nasal polyps, chronic rhinosinusitis, middle ear disease, neonatal ARDS/ICU admission as neonate